Fresenius Obtains Reimbursement Approval for Removab in Belgium

Fresenius Biotech said the Belgian Health Ministry added its trifunctional antibody Removab to the list of reimbursable medications as of Oct. 1. The use of Removab will be reimbursed if the eligible patients also fulfill defined additional clinical inclusion criteria, the company said in an e-mailed statement today.

To contact the editor responsible for this story: Mariajose Vera at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.